Show simple item record

hal.structure.identifier
dc.contributor.authorMennini, F.S.*
hal.structure.identifier
dc.contributor.authorMarcellusi, A.*
hal.structure.identifier
dc.contributor.authorGraf von der Schulenburg, J.M.*
hal.structure.identifier
dc.contributor.authorGray, A.*
hal.structure.identifierLaboratoire d'Economie et de Gestion des Organisations de Santé [Legos]
hal.structure.identifier
dc.contributor.authorLévy, Pierre
HAL ID: 10931
*
hal.structure.identifier
dc.contributor.authorSciattella, , P.*
hal.structure.identifier
dc.contributor.authorSoro, M.*
hal.structure.identifier
dc.contributor.authorStaffiero, G.*
hal.structure.identifier
dc.contributor.authorZeidler, J.*
hal.structure.identifier
dc.contributor.authorMaggioni, A.*
hal.structure.identifier
dc.contributor.authorSchmieder, R. E.*
dc.date.accessioned2014-01-07T14:25:29Z
dc.date.available2014-01-07T14:25:29Z
dc.date.issued2015
dc.identifier.issn1618-7598
dc.identifier.urihttps://basepub.dauphine.fr/handle/123456789/12354
dc.language.isoenen
dc.subjectHypertension
dc.subjectHypertensive therapy
dc.subjectCost of illness
dc.subjectAdherence
dc.subjectEconomic burden
dc.subject.ddc334en
dc.subject.classificationjelE.E6.E60en
dc.subject.classificationjelI.I1.I18en
dc.titleCost of poor adherence to anti-hypertensive therapy in five European countries
dc.typeArticle accepté pour publication ou publié
dc.contributor.editoruniversityotherEconomic Evaluation and HTA (EEHTA), CEIS, Faculty of Economics, University of Rome “Tor Vergata”
dc.contributor.editoruniversityotherMarket Access Department, Daiichi Sankyo Europe
dc.contributor.editoruniversityotherDepartment of Economics and Business, CRES, Universitat Pompeu Fabra Barcelona
dc.contributor.editoruniversityotherCenter for Health Economics Research Hannover(CHERH), Leibniz Universität Hannover
dc.contributor.editoruniversityotherAssociazione Nazionale Medici Cardiologi Ospedalieri Research Center
dc.contributor.editoruniversityotherDepartment of Nephrology and Hypertension, University Hospital Erlangen
dc.description.abstractenThe financial burden for EU health systems associated with cardiovascular disease (CV) has been estimated to be nearly €110 billion in 2006, corresponding to 10 % of total healthcare expenditure across EU or a mean €223 annual cost per capita. The main purpose of this study is to estimate the costs related to hypertension and the economic impact of increasing adherence to anti-hypertensive therapy in five European countries (Italy, Germany, France, Spain and England). A probabilistic prevalence-based decision tree model was developed to estimate the direct costs of CV related to hypertension (CV defined as: stroke, heart attack, heart failure) in five European countries. Our model considered adherence to hypertension treatment as a main driver of blood pressure (BP) control (BP < 140/90 mmHg). Relative risk of CV, based on controlled or uncontrolled BP group, was estimated from the Framingham Heart Study and national review data. Prevalence and cost data were estimated from national literature reviews. A national payer (NP) perspective for 10 years was considered. Probabilistic sensitivity analysis was performed in order to evaluate uncertainty around the results (given as 95 % confidence intervals). The model estimated a total of 8.6 million (1.4 in Italy, 3.3 in Germany, 1.2 in Spain, 1.8 in France and 0.9 in England) CV events related to hypertension over the 10-year time horizon. Increasing the adherence rate to anti-hypertensive therapy to 70 % (baseline value is different for each country) would lead to 82,235 fewer CV events (24,058 in Italy, 7,870 in Germany, 18,870 in Spain, 24,855 in France and 6,553 in England). From the NP perspective, the direct cost associated with hypertension was estimated to be €51.3 billion (8.1 in Italy, 17.1 in Germany, 12.2 in Spain, 8.8 in France and 5.0 in England). Increasing adherence to anti-hypertensive therapy to 70 % would save a total of €332 million (CI 95 %: €319–346 million) from the NPs perspective. This study is the first attempt to estimate the economic impact of non-adherence amongst patients with diagnosed hypertension in Europe, using data from five European countries (Italy, France, Germany, Spain and England).
dc.relation.isversionofjnlnameThe European Journal of Health Economics
dc.relation.isversionofjnlvol16
dc.relation.isversionofjnlissue1
dc.relation.isversionofjnldate2015
dc.relation.isversionofjnlpages65-72
dc.relation.isversionofdoi10.1007/s10198-013-0554-4
dc.relation.isversionofjnlpublisherSpringer-Medizin-Verl..
dc.subject.ddclabelEconomie socialeen
dc.relation.forthcomingnonen
dc.description.ssrncandidatenon
dc.description.halcandidateoui
dc.description.readershiprecherche
dc.description.audienceInternational
dc.relation.Isversionofjnlpeerreviewedoui
dc.date.updated2016-03-24T13:57:01Z
hal.identifierhal-01616348*
hal.version1*
hal.update.actionupdateMetadata*
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record